Gilead Sciences (GILD) Non-Current Assets (2009 - 2026)
Gilead Sciences' (GILD) quarterly Non-Current Assets came in at $37.6 billion in Q1 2026, down 4.8% YoY from $39.5 billion in Q1 2025, and down 7.48% on a QoQ basis from $40.7 billion in Q4 2025.
Gilead Sciences (GILD) Non-Current Assets (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Non-Current Assets data on file, last reported at $37.6 billion in Q1 2026.
- Quarterly Non-Current Assets fell 4.8% year-over-year to $37.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.0 billion (changed 0.24% YoY) and the FY2025 annual result came in at $40.7 billion, up 2.16% from the prior year.
- Non-Current Assets eased to $37.6 billion in Q1 2026, from $40.7 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $50.5 billion in Q1 2022 to a low of $37.6 billion in Q1 2026.
- A 5-year average of $44.1 billion and a median of $42.3 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets retreated 14.33% — and 2025, when it gained 2.3%.
- Tracing GILD's Non-Current Assets over 5 years: stood at $48.7 billion in 2022, then declined by 5.52% to $46.0 billion in 2023, then declined by 13.51% to $39.8 billion in 2024, then grew by 2.16% to $40.7 billion in 2025, then slipped by 7.48% to $37.6 billion in 2026.
- The last three Non-Current Assets figures came in at $37.6 billion (Q1 2026), $40.7 billion (Q4 2025), and $40.7 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 470.14 Bn | 463.57 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 379.19 Bn | 372.05 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 302.86 Bn | 295.17 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 236.75 Bn | 222.76 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 182.65 Bn | 179.47 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 161.71 Bn | 150.01 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.55 Bn | 101.38 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.42 Bn |
| Mar 31, 2026 | 37.64 Bn |
| Dec 31, 2025 | 40.68 Bn |
| Sep 30, 2025 | 40.66 Bn |
| Jun 30, 2025 | 41.00 Bn |
| Mar 31, 2025 | 39.53 Bn |
| Dec 31, 2024 | 39.82 Bn |
| Sep 30, 2024 | 39.75 Bn |
| Jun 30, 2024 | 41.26 Bn |
| Mar 31, 2024 | 42.25 Bn |
| Dec 31, 2023 | 46.04 Bn |
| Sep 30, 2023 | 46.39 Bn |
| Jun 30, 2023 | 48.05 Bn |
| Mar 31, 2023 | 48.42 Bn |
| Dec 31, 2022 | 48.73 Bn |
| Sep 30, 2022 | 49.00 Bn |
| Jun 30, 2022 | 49.70 Bn |
| Mar 31, 2022 | 50.45 Bn |
| Dec 31, 2021 | 53.18 Bn |
| Sep 30, 2021 | 53.11 Bn |